Prevalence of type 2 diabetes mellitus and association of HbA1c with severity of coronary artery disease in patients presenting as non-diabetic acute coronary syndrome

The Egyptian Heart Journal

Table 2 Therapeutic interventions and thrombolytic drugs used in STEMI patient population

		N (%)
Therapeutic intervention	Thrombolysis	108 (64.30)
	Primary PCI	20 (11.90)
	Late presentation	36 (21.42)
	Thrombolysis contraindicated	04 (2.38)
	Total	168 (100)
Thrombolytic drug	Streptokinase	49 (45.37)
	Tenecteplase	41 (37.97)
	Reteplase	18 (16.66)
	Total	108 (100)